Exemption of bulk drugs from price control

4591. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to state:

(a) what are the names of the bulk drugs and companies which applied for exemption of such bulk drugs from price control on the ground of R and D after the inception of DPCO, 1987;

(b) what are the names of the bulk drugs in respect of which exemption have been granted and upto what period;

(c) what are the drugs in respect of which exemption is yet to be granted and what are the reasons for withholding the exemption;

(d) whether it is a fact that Government have continued the process of exemption even when the new policy is in the offing but the process of addition of drugs to the price controlled list has been given up in the interest of producers, mostly multinationals; and

(e) if so, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) To the extent available information has been given in the Statement enclosed. (*See* below)

(d) and (e) The exemption on the ground of R&D is based on the existing guidelines issued under DPCO 1987 which is presently in force.

Statement

Import of drugs and penultimates

4592. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government Policy is encouraging more and more imports of drugs and penultimates|intermediates as the ratio parameters are totally fauly and ineffective;

Statement

Sl. No.	Name of the bulk drug	Name of the Company	Present Status
1	2	3	4
1	Ranitidine	M/s. Ranbaxy Labs. Ltd.	Exemption granted upto 30-9-93
2	Nalidixic Acid . . .	Do.	Do. 31-10-92
3	Daxycycline Hyclate Hcl . .	Do.	Pending
4	Metoclopramide . . .	M/s. IPCA Laboratories	Exemption granted upto 31-12-93
5	Dextropropoxyphene . .	M/s Wockhardt Ltd	Do. 25-4-90
6	Providone Iodine . . .	Do.	Do. 31-12-95
7	Salbutamol	M/s. Cipla Ltd.	Do. 31-8-93
8	Ephedrine	M/s. Malladi Drugs	Do. 31-3-92

1	2	3	4	
9	Ranitidine	M/s. Globe Organics	Do.	31-3-93
10	Amoxycillin Sodium	M/s. Duphar Interfran	Do.	31-3-92
11	Verapamil Hcl	M/s. Associated Drug Co. Pvt. Ltd.	Do.	28-2-94
12	Metroclopramide Hcl	M/s. Infar (I) Ltd.	Do.	31-1-94
13	Naproxen	M/s. Rallis India Ltd.	Do.	30-9-91
14	Theophylline	M/s. Pefco Industries Ltd.	Do.	December, 92
15	Betamethasone Disodium Phosphate	M/s. Glaxo India Ltd.	Do.	31-12-94
16	Ephedrine Hcl	M/s. Emmellen Biotech Pharma Ltd.	The company was issued rejection on the ground that the proposal did not fulfil the requisite conditions for grant of exemption from price control.	
17	Diclofence Sodium	M/s. Unique Chemicals	Under consideration of Expert Group on Technology Issues.	
18	Timolol Maleate	M/s. F.D.C. Ltd.;		
19	Cephalexin	M/s. Lupin Labs.		
20	Rifampicin	Do.		

Import of drugs and penultimates

4592. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government Policy is encouraging more and more imports of drugs and penultimates/intermediates as the ratio parameters are totally faulty and ineffective;

(b) whether it is a fact that Government have not issued guidelines in respect of computation of value of production and consumption of indigenous bulk drugs;

(c) if so, the reasons therefor;

(d) whether it is also a fact that the value of imports of intermediates and penultimates are not covered in the ratio parameter;

(e) if so, whether it is a fact that import bill of imports of intermediates have gone up considerably;

(f) whether it is also a fact that number of units producing from basic stages have shifted to intermediates stages; and

(g) if so, the detail of instances came to the notice of Government and action taken thereon?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) and (c) The requirements for computing the value of production as well as of the consumption of indigenous bulk drugs have been announced in the Drug Policy, 1986 as given below:

I. (i) *Production*: The ratio between ex-factory value of production of bulk drugs and formulations should be as follows for non-FERA companies:

Turn Over	*Ratio Parameter*
Upto Rs. 10 crores	1 : 10
Beyond Rs. 10 crores	1 : 7